Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK

Proceedings of the National Academy of Sciences of the United States of America
Idit Sagiv-BarfiRonald Levy

Abstract

Monoclonal antibodies can block cellular interactions that negatively regulate T-cell immune responses, such as CD80/CTLA-4 and PD-1/PD1-L, amplifying preexisting immunity and thereby evoking antitumor immune responses. Ibrutinib, an approved therapy for B-cell malignancies, is a covalent inhibitor of BTK, a member of the B-cell receptor (BCR) signaling pathway, which is critical to the survival of malignant B cells. Interestingly this drug also inhibits ITK, an essential enzyme in Th2 T cells and by doing so it can shift the balance between Th1 and Th2 T cells and potentially enhance antitumor immune responses. Here we report that the combination of anti-PD-L1 antibody and ibrutinib suppresses tumor growth in mouse models of lymphoma that are intrinsically insensitive to ibrutinib. The combined effect of these two agents was also documented for models of solid tumors, such as triple negative breast cancer and colon cancer. The enhanced therapeutic activity of PD-L1 blockade by ibrutinib was accompanied by enhanced antitumor T-cell immune responses. These preclinical results suggest that the combination of PD1/PD1-L blockade and ibrutinib should be tested in the clinic for the therapy not only of lymphoma but also in other hema...Continue Reading

References

Sep 3, 1996·Proceedings of the National Academy of Sciences of the United States of America·A Y HuangE M Jaffee
Jul 20, 1999·Clinical & Experimental Metastasis·M LelekakisR L Anderson
Aug 7, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jun KonishiMasaharu Nishimura
Dec 1, 2004·Proceedings of the National Academy of Sciences of the United States of America·R Houston ThompsonEugene D Kwon
Apr 20, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yuichiro OhigashiYoshiyuki Nakajima
May 30, 2006·Advances in Immunology·Alan J KormanJames P Allison
Aug 7, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jiali LiRonald Levy
Jan 5, 2008·Annual Review of Immunology·Mary E KeirArlene H Sharpe
Oct 4, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Je-In YounDmitry I Gabrilovich
Jul 10, 2010·Proceedings of the National Academy of Sciences of the United States of America·Lee A HonigbergJoseph J Buggy
Jun 2, 2011·Nature Reviews. Drug Discovery·Vernon K SondakPeter Kirkpatrick
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Oct 10, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ranjana H AdvaniNathan H Fowler
Apr 5, 2013·The New England Journal of Medicine·Antoni RibasJedd Wolchok
Jun 4, 2013·The New England Journal of Medicine·Omid HamidAntoni Ribas
Jun 4, 2013·The New England Journal of Medicine·Jedd D WolchokMario Sznol
Mar 7, 2014·Science Translational Medicine·Dmitriy ZamarinJames P Allison
Apr 30, 2014·The Journal of Experimental Medicine·Muhammad Zaeem NomanSalem Chouaib
Jun 7, 2014·Cancer Immunology Research·Zachary A CooperJennifer A Wargo
Jul 30, 2014·Proceedings of the National Academy of Sciences of the United States of America·KiBem KimShibin Zhou
Oct 22, 2014·Drugs·Raewyn M Poole
Dec 9, 2014·The New England Journal of Medicine·Stephen M AnsellPhilippe Armand

❮ Previous
Next ❯

Citations

Feb 10, 2016·Current Hematologic Malignancy Reports·Ciara L Freeman, John G Gribben
Oct 4, 2015·Biochimica Et Biophysica Acta·Yi XiaKen H Young
Jan 19, 2016·Trends in Immunology·Meng Michelle XuYang-Xin Fu
Nov 8, 2015·Progress in Lipid Research·Laurence Balas, Thierry Durand
Nov 12, 2015·Biochimica Et Biophysica Acta·Nicole S NicholasAlan G Ramsay
Jan 19, 2016·Blood Reviews·Nitin Jain, Susan O'Brien
Mar 12, 2016·Cell·A Karolina Palucka, Lisa M Coussens
Sep 29, 2015·Cancer Treatment Reviews·Hazel LoteIan Chau
Jun 26, 2015·Scandinavian Journal of Immunology·A BerglöfC I E Smith
Jul 15, 2015·Blood·Arnon P Kater, Gerritje J W van der Windt
May 12, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A Marabelle, R Houot
Jan 26, 2016·The FEBS Journal·Gita ThanarajasingamStephen M Ansell
Dec 8, 2015·Hematology·Kristie A Blum
Nov 3, 2016·Nature Reviews. Clinical Oncology·Aaron GoodmanRazelle Kurzrock
Nov 26, 2016·Cancers·Smitha MenonGrace Dy
Oct 1, 2016·Expert Opinion on Drug Metabolism & Toxicology·Prithviraj BoseMichael J Keating
Dec 30, 2016·Nature Reviews. Clinical Oncology·Anas YounesJulie Vose
Apr 22, 2017·Cancer Treatment Reviews·Leo RascheFaith E Davies
Oct 25, 2016·Chemical Record : an Official Publication of the Chemical Society of Japan ... [et Al.]·Mercedes Zurro, Olga García Mancheño
Mar 22, 2018·Journal of Clinical Medicine·Robert CampbellEliza A Hawkes
Oct 14, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Georgios ChamilosDimitrios P Kontoyiannis
Mar 28, 2018·Journal of Hematology & Oncology·Rosemarie Tremblay-LeMayHong Chang
Oct 4, 2017·Angewandte Chemie·Bayard R HuckKlaus Urbahns
Apr 21, 2018·Annual Review of Immunology·Amy H AndreottiLeslie J Berg
May 17, 2018·Leukemia & Lymphoma·Christopher PleyerClare Sun
May 14, 2018·Applied Microbiology and Biotechnology·Xuyao ZhangDianwen Ju
Sep 28, 2017·Journal of Experimental & Clinical Cancer Research : CR·Chenglong YueXuejiao Liu
Jul 27, 2018·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Muhammad Salman FaisalSalman Fazal
Nov 6, 2018·Drugs·Caspar da Cunha-Bang, Carsten Utoft Niemann
Nov 21, 2017·F1000Research·Prithviraj Bose, Varsha Gandhi
Oct 20, 2018·Current Hematologic Malignancy Reports·Bei HuNilanjan Ghosh
Feb 20, 2018·Molecular Cancer·Simar Pal SinghRudi W Hendriks
Mar 22, 2019·The Cancer Journal·Vidula V SukhatmeVikas P Sukhatme
Dec 10, 2017·Hematology·James L Rubenstein
Apr 17, 2019·The Journal of Immunology : Official Journal of the American Association of Immunologists·Philipp HaselmayerRoland Grenningloh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

Related Papers

The New England Journal of Medicine
Julie R BrahmerJon M Wigginton
Proceedings of the National Academy of Sciences of the United States of America
Ping YuThomas A Waldmann
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Ranjana H AdvaniNathan H Fowler
© 2022 Meta ULC. All rights reserved